Ex vivo treatment of malignant pleural effusions with the bispecific antibody MT110 targeting EPCAM and CD3

被引：0
|
作者：
Witthauer, J. [1 ,2 ]
Schlereth, B. [2 ]
Brischwein, K. [2 ]
Jauch, K. -W. [1 ]
Mayer, B. [1 ]
机构：
[1] Univ Munich, LMU, Dept Surg, Munich, Germany
[2] Micromet AG, Munich, Germany
来源：
ONKOLOGIE | 2008年 / 31卷
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
引用
收藏
页码：56 / 56
页数：1
相关论文
共 50 条
  • [31] A novel targeted GPC3/CD3 bispecific antibody for the treatment hepatocellular carcinoma
    Lin Yu
    Xi Yang
    Nan Huang
    Lang, Qiao-Li
    He, Qi-Lin
    Wang Jian-Hua
    Ge Liang-Peng
    CANCER BIOLOGY & THERAPY, 2020, 21 (07) : 597 - 603
  • [32] Tetravalent anti-CD20/CD3 bispecific antibody for the treatment of B cell lymphoma
    Lu, Chia-Yen
    Chen, Gregory J.
    Tai, Pei-Han
    Yang, Yu-Chen
    Hsu, Yu-Shen
    Chang, Mingi
    Hsu, Chuan-Lung
    BIOCHEMICAL AND BIOPHYSICAL RESEARCH COMMUNICATIONS, 2016, 473 (04) : 808 - 813
  • [33] A Bispecific Antibody Targeting CD117 and CD3 Enables T Cell Mediated Killing of CD117-Expressing Healthy and Malignant Hematopoietic Cells
    Kiefer, Jonathan D.
    Myburgh, Renier
    Russkamp, Norman F.
    Volta, Laura
    Guggisberg, Adrian
    Abdelmotaleb, Omar
    Mock, Jacqueline
    Neri, Dario
    Manz, Markus G.
    BLOOD, 2021, 138
  • [34] A gB/CD3 bispecific BiTE antibody construct for targeting Human Cytomegalovirus-infected cells
    Charlotte U. Brey
    Julia Proff
    Natascha Teufert
    Benjamin Salzer
    Johannes Brozy
    Markus Münz
    Jochen Pendzialek
    Armin Ensser
    Wolfgang Holter
    Manfred Lehner
    Scientific Reports, 8
  • [35] A gB/CD3 bispecific BiTE antibody construct for targeting Human Cytomegalovirus-infected cells
    Brey, Charlotte U.
    Proff, Julia
    Teufert, Natascha
    Salzer, Benjamin
    Brozy, Johannes
    Muenz, Markus
    Pendzialek, Jochen
    Ensser, Armin
    Holter, Wolfgang
    Lehner, Manfred
    SCIENTIFIC REPORTS, 2018, 8
  • [36] In vivo assessment of AICD and cytokine release upon treatment of OKT3 and CD3 bispecific antibody in homozygous CD3EDG HuGEMM™
    He, Daniel X. F.
    CANCER RESEARCH, 2022, 82 (12)
  • [37] Basic Science Ovarian Cancer Solitomab, an EpCAM/CD3 bispecific antibody (BITE), is highly active against primary chemotherapy resistant ovarian cancer cell lines in vitro and fresh tumor cells ex vivo
    English, Diana P.
    Bellone, Stefania
    Schwab, Carlton L.
    Roque, Dana M.
    Chatterjee, Sudeshna
    Ratner, Elena
    Schwartz, Peter E.
    Rutherford, Thomas J.
    Santin, Alessandro D.
    GYNECOLOGIC ONCOLOGY, 2015, 136 (02) : 401 - 401
  • [38] Immune-mediated liver injury of the cancer therapeutic antibody catumaxomab targeting EpCAM, CD3 and Fcγ receptors
    Borlak, Juergen
    Laenger, Florian
    Spanel, Reinhard
    Schoendorfer, Georg
    Dittrich, Christian
    ONCOTARGET, 2016, 7 (19) : 28059 - 28074
  • [39] A novel dual CAB nectin-4 x CD3 bispecific antibody targeting solid tumors
    Lucas, Matthew
    Cugnetti, Ana Paula
    Liu, Haizhen
    Xing, Charles
    Wang, Jing
    McNeeley, Patricia
    Wheeler, Christina
    Joyner, Solmarie
    Johnson, Kyrie
    Woodard, Kathryn
    Zhou, Wei
    Chang, Cathy
    Frey, Gerhard
    Boyle, William J.
    Short, Jay M.
    CANCER RESEARCH, 2023, 83 (07)
  • [40] A Novel Bispecific Antibody Targeting CD3 and Lewis Y with Potent Therapeutic Efficacy against Gastric Cancer
    Chen, Jie
    Pan, Zhidi
    Han, Lei
    Zhou, Yuexian
    Zong, Huifang
    Wang, Lei
    Sun, Rui
    Jiang, Hua
    Xie, Yueqing
    Yuan, Yunsheng
    Wu, Mingyuan
    Bian, Yanling
    Zhang, Baohong
    Zhu, Jianwei
    BIOMEDICINES, 2021, 9 (08)
12345